Cargando…
Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells
A family of monomodified bovine serum albumin (BSA) linked to methotrexate (MTX) through a variety of spacers was prepared. All analogues were found to be prodrugs having low MTX-inhibitory potencies toward dihydrofolate reductase in a cell-free system. The optimal conjugates regenerated their antip...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778984/ https://www.ncbi.nlm.nih.gov/pubmed/35056966 http://dx.doi.org/10.3390/pharmaceutics14010071 |
_version_ | 1784637460516438016 |
---|---|
author | Cooper, Itzik Schnaider-Beeri, Michal Fridkin, Mati Shechter, Yoram |
author_facet | Cooper, Itzik Schnaider-Beeri, Michal Fridkin, Mati Shechter, Yoram |
author_sort | Cooper, Itzik |
collection | PubMed |
description | A family of monomodified bovine serum albumin (BSA) linked to methotrexate (MTX) through a variety of spacers was prepared. All analogues were found to be prodrugs having low MTX-inhibitory potencies toward dihydrofolate reductase in a cell-free system. The optimal conjugates regenerated their antiproliferative efficacies following entrance into cancerous glioma cell lines and were significantly superior to MTX in an insensitive glioma cell line. A BSA–MTX conjugate linked through a simple ethylene chain spacer, containing a single peptide bond located 8.7 Å distal to the protein back bone, and apart from the covalently linked MTX by about 12 Å, was most effective. The inclusion of an additional disulfide bond in the spacer neither enhanced nor reduced the killing potency of this analogue. Disrupting the native structure of the carrier protein in the conjugates significantly reduced their antiproliferative activity. In conclusion, we have engineered BSA–MTX prodrug analogues which undergo intracellular reactivation and facilitate antiproliferative activities following their entrance into glioma cells. |
format | Online Article Text |
id | pubmed-8778984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87789842022-01-22 Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells Cooper, Itzik Schnaider-Beeri, Michal Fridkin, Mati Shechter, Yoram Pharmaceutics Article A family of monomodified bovine serum albumin (BSA) linked to methotrexate (MTX) through a variety of spacers was prepared. All analogues were found to be prodrugs having low MTX-inhibitory potencies toward dihydrofolate reductase in a cell-free system. The optimal conjugates regenerated their antiproliferative efficacies following entrance into cancerous glioma cell lines and were significantly superior to MTX in an insensitive glioma cell line. A BSA–MTX conjugate linked through a simple ethylene chain spacer, containing a single peptide bond located 8.7 Å distal to the protein back bone, and apart from the covalently linked MTX by about 12 Å, was most effective. The inclusion of an additional disulfide bond in the spacer neither enhanced nor reduced the killing potency of this analogue. Disrupting the native structure of the carrier protein in the conjugates significantly reduced their antiproliferative activity. In conclusion, we have engineered BSA–MTX prodrug analogues which undergo intracellular reactivation and facilitate antiproliferative activities following their entrance into glioma cells. MDPI 2021-12-28 /pmc/articles/PMC8778984/ /pubmed/35056966 http://dx.doi.org/10.3390/pharmaceutics14010071 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cooper, Itzik Schnaider-Beeri, Michal Fridkin, Mati Shechter, Yoram Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells |
title | Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells |
title_full | Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells |
title_fullStr | Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells |
title_full_unstemmed | Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells |
title_short | Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells |
title_sort | albumin–methotrexate prodrug analogues that undergo intracellular reactivation following entrance into cancerous glioma cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778984/ https://www.ncbi.nlm.nih.gov/pubmed/35056966 http://dx.doi.org/10.3390/pharmaceutics14010071 |
work_keys_str_mv | AT cooperitzik albuminmethotrexateprodruganaloguesthatundergointracellularreactivationfollowingentranceintocancerousgliomacells AT schnaiderbeerimichal albuminmethotrexateprodruganaloguesthatundergointracellularreactivationfollowingentranceintocancerousgliomacells AT fridkinmati albuminmethotrexateprodruganaloguesthatundergointracellularreactivationfollowingentranceintocancerousgliomacells AT shechteryoram albuminmethotrexateprodruganaloguesthatundergointracellularreactivationfollowingentranceintocancerousgliomacells |